SCHEMBL2259596

SCHEMBL2259596

COC(C)=C(C(=O)O)c1ccccc1COc1cccc(C(F)(F)F)n1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 2/20 0.39
MRGPRX4 Q96LA9 4/20 0.37
OPRL1 P41146 1/20 0.36
HIF1A Q16665 2/20 0.36
SYK P43405 1/20 0.36
P2RX7 Q99572 1/20 0.36
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
TP53 P04637 1/20 0.34
HTT P42858 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
CD274 Q9NZQ7 2/20 0.34
MBOAT4 Q96T53 1/20 0.34
PDCD1 Q15116 1/20 0.34
ACKR3 P25106 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3892676 1.00 TAS2R14 (0.39) TAS2R14MRGPRX4OPRL1HIF1ASYK
SCHEMBL6159533 0.90 TAS2R14 (0.39) TAS2R14MRGPRX4OPRL1HIF1ASYK
SCHEMBL28336662 0.86 HCRTR1 (0.37) MRGPRX4OPRL1HIF1AP2RX7HCRTR1
SCHEMBL4648199 0.81 TAS2R14 (0.39) TAS2R14MRGPRX4OPRL1HIF1ASYK
SCHEMBL31634978 0.81 TAS2R14 (0.40) TAS2R14MRGPRX4P2RX7HCRTR1HCRTR2
SCHEMBL20552906 0.81 TAS2R14 (0.40) TAS2R14MRGPRX4P2RX7HCRTR1HCRTR2
SCHEMBL30748265 0.81 TAS2R14 (0.37) TAS2R14MRGPRX4OPRL1HIF1ASYK
SCHEMBL1132765 0.81 TAS2R14 (0.37) TAS2R14MRGPRX4OPRL1HIF1ASYK
SCHEMBL1132769 0.81 TAS2R14 (0.37) TAS2R14MRGPRX4OPRL1HIF1ASYK
SCHEMBL4089901 0.81 PTGS1 (0.36) MRGPRX4OPRL1HIF1ASYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050085389-A1 Seed treatment compositions SYNGENTA CROP PROTECTION, INC. 2005-04-21 US claimed
EP-1267617-B1 FUNGICIDAL METHOD HERCULES INC (US) 2005-02-09 EP claimed
US-10206391-B2 Strobilurin formulations VIVE CROP PROTECTION INC. (CA) 2019-02-19 US disclosed
US-20140364310-A1 STROBILURIN FORMULATIONS VIVE CROP PROTECTION INC. (CA) 2014-12-11 US disclosed
US-8008230-B2 Synergistic antifungal DDAC compositions JANSSEN PHARMACEUTICA N.V. (BE) 2011-08-30 US disclosed
JP-2010168393-A SYNERGISTIC SEED TREATMENT COMPOSITION SYNGENTA PARTICIPATIONS AG 2010-08-05 JP disclosed
US-20070293395-A1 Use of 2-Substituted Pyrimidines for Combating Nematode Diseases of Plants BASF AKTIENGESELLSCHAFT (DE) 2007-12-20 US disclosed
CN-1332604-C Synergistic Seed Treatment Composition SYNGENTA PARTICIPATIONS AG (CH) 2007-08-22 CN disclosed
US-20070142410-A1 Synergistic antifungal ddac compositions JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-21 US disclosed
EP-1793676-A1 USE OF 2-SUBSTITUTED PYRIMIDINES FOR COMBATING NEMATODE OF PLANTS BASF AKTIENGESELLSCHAFT (DE) 2007-06-13 EP disclosed
WO-2006032526-A1 USE OF 2-SUBSTITUTED PYRIMIDINES FOR COMBATING NEMATODE OF PLANTS BASF AKTIENGESELLSCHAFT (DE) 2006-03-30 WO disclosed
US-20050085389-A1 Seed treatment compositions SYNGENTA CROP PROTECTION, INC. 2005-04-21 US disclosed
US-20050085389-A1 Seed treatment compositions SYNGENTA CROP PROTECTION, INC. 2005-04-21 US disclosed
CN-1604738-A Synergistic Seed Treatment Composition SYNGENTA PARTICIPATIONS AG (CH) 2005-04-06 CN disclosed
US-20050065031-A1 Synergistic seed treatment compositions LANXESS CORPORATION 2005-03-24 US disclosed
WO-2004082383-A1 USE OF TRIAZOLOPYRIMIDINES FOR COMBATING NEMATODE DISEASES OF PLANTS BASF AKTIENGESELLSCHAFT (DE) 2004-09-30 WO disclosed
EP-1450606-A1 SYNERGISTIC SEED TREATMENT COMPOSITIONS Syngenta Participations AG (CH) 2004-09-01 EP disclosed
WO-2003045147-A1 SYNERGISTIC SEED TREATMENT COMPOSITIONS SYNGENTA PARTICIPATIONS AG (CH) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364310-A1 STROBILURIN FORMULATIONS CD63, SNU13, SNX1 TAS2R14 4451/4885MRGPRX4 3478/4885OPRL1 4869/4885
US-10206391-B2 Strobilurin formulations CD63, SNU13, SNX1 TAS2R14 4451/4885MRGPRX4 3478/4885OPRL1 4869/4885
US-20070293395-A1 Use of 2-Substituted Pyrimidines for Combating Nematode Diseases of Plants TYMS, UMPS, NUDT1 TAS2R14 3049/4885MRGPRX4 798/4885OPRL1 2863/4885
US-20070142410-A1 Synergistic antifungal ddac compositions AADAC, BRD3, DDC TAS2R14 471/4885MRGPRX4 3820/4885OPRL1 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.